Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Boehringer Ingelheim
Baxter
Mallinckrodt
Johnson and Johnson

Last Updated: June 24, 2022

Lifitegrast - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

What are the generic drug sources for lifitegrast and what is the scope of freedom to operate?

Lifitegrast is the generic ingredient in one branded drug marketed by Novartis and is included in one NDA. There are sixteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Lifitegrast has one hundred and fifty-two patent family members in twenty-five countries.

Two suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for lifitegrast
Recent Clinical Trials for lifitegrast

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of WaterlooPhase 4
Research Insight LLCPhase 4
NovartisEarly Phase 1

See all lifitegrast clinical trials

Generic filers with tentative approvals for LIFITEGRAST
Applicant Application No. Strength Dosage Form
See Plans and PricingSee Plans and Pricing5%SOLUTION/DROPS;OPHTHALMIC

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Anatomical Therapeutic Chemical (ATC) Classes for lifitegrast
Paragraph IV (Patent) Challenges for LIFITEGRAST
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
XIIDRA Ophthalmic Solution lifitegrast 5% 208073 4 2020-07-13

US Patents and Regulatory Information for lifitegrast

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Novartis XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Novartis XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Novartis XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Novartis XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for lifitegrast

Country Patent Number Title Estimated Expiration
European Patent Office 3195861 COMPOSITIONS ET PROCÉDÉS DE TRAITEMENT DES TROUBLES DE LA SÈCHERESSE DE L' IL (COMPOSITIONS AND METHODS FOR TREATMENT OF DRY EYE DISORDERS) See Plans and Pricing
Cyprus 1116045 See Plans and Pricing
Denmark 1682537 See Plans and Pricing
Canada 2879982 INHIBITEUR DE LFA-1 ET POLYMORPHE DE CELUI-CI (LFA-1 INHIBITOR AND POLYMORPH THEREOF) See Plans and Pricing
China 102056485 Topical LFA-1 antagonists for use in localized treatment of immune related disorders See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
McKesson
Moodys
Dow
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.